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Abstract
Pancreatitis-associated protein (PAP)-I and -II, lectin-related secretory proteins, are members of the regenerating gene 
(Reg) family. Although expression of PAP-I was found in the dorsal root ganglion (DRG) neurons following peripheral 
nerve injury and cystitis, whether PAP-II could be expressed in DRG neurons in chronic pain models remains unclear. 
The present study shows an inflammation- and nerve injury-triggered expression of PAP-II in rat DRG neurons. In situ 
hybridization showed that only a few DRG neurons normally contained PAP-I and -II mRNAs. After peripheral 
inflammation, PAP-I and -II mRNAs were present in over half of small DRG neurons. Such an elevated expression of PAP-
I and -II reached the peak level on the second day. Immunostaining showed that the expression of PAP-II was mostly 
increased in the isolectin B4-positive subset of small DRG neurons after inflammation. Furthermore, the expression of 
PAP-II was also induced in DRG neurons after peripheral nerve injury. Interestingly, PAP-II expression was shifted from 
small neurons on day 2 to large DRG neurons that expressed neuropeptide Y during the later post-injury days. These 
results suggest that PAP-II may play potential roles in the modulation of spinal sensory pathways in pathological pain 
states.
Background
Tissue inflammation or lesions to the nervous system
may result in enhanced responses to noxious stimuli or
pain evoked by normally innocuous stimuli [1-6]. Accu-
mulated evidence has shown that many neurotransmit-
ters/neuromodulators, receptors, ion channels and
signaling molecules are involved in the generation of
chronic pain [1,2,6,7]. Nociceptors are known to be sensi-
tized by a number of inflammatory mediators released
from damaged tissues, such as ATP, nitric oxide, interleu-
kin 1, interleukin 6, and tumour necrosis factor alpha
(TNF-α) [1,2,6]. Moreover, changes in the gene expres-
sion profiles of the dorsal root ganglion (DRG) and that of
the dorsal spinal cord following peripheral tissue inflam-
mation or peripheral nerve injury may contribute to the
mechanisms for the initiation and development of patho-
logical pain [4,6,8]. Therefore, it is interesting to identify
the molecules that are strongly regulated in the spinal
sensory pathways following peripheral tissue inflamma-
tion or nerve injury.
Pancreatitis-associated protein-I (PAP-I) is known as
PAP 1 and peptide 23 in the rat, and regenerating (Reg)
islet-derived protein 3 beta (Reg III-β) in the mouse, and
PAP-II known as Reg III in the rat and Reg III-α in the
mouse. They are lectin-related secretory proteins and
belong to the Reg family which contains similar proteins
found in the pancreas and gastrointestinal tract in physi-
ological and/or pathological conditions [9-11]. Reg is first
isolated from a regenerating islet cDNA library [12] and
encodes a secretory protein with a growth stimulating
effect on pancreatic β cells [10,13]. Based on the primary
structures of the proteins, the members of the Reg family
are grouped into three subclasses, namely type I, II and
III [10,14-18]. PAP-I and -II are members of the type III
subclass and encoded by gene PAP-I and PAP-II, respec-
tively.
Previous studies suggest that both PAP-I and -II are
involved in the modulation of inflammatory responses.
During acute pancreatitis, PAP-I may contribute to stress
response to control bacterial proliferation [9]. In pancre-
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atic AR4-2J cells, PAP-I is one of the effectors for the
TNF-α-induced apoptosis inhibition [19]. Although PAP-
II is first isolated as a pancreatic secretory protein that
contributes to pancreatic regeneration, it is up-regulated
during the acute phase of pancreatitis and likely modu-
lates the inflammatory environment of pancreatitis [9,20-
24]. PAP-II is found to inhibit TNF-α-mediated inflam-
matory responses [25,26]. In the exocrine pancreas, PAP-
I is associated with pancreatic acinar cell and protects
cells from oxidative stress and TNF-α-induced pancreatic
stress [19,27]. Moreover, expre s s i o n  o f  P A P - I I  i s  a l s o
increased in gut epithelial cells in human inflammatory
bowel disease [28].
Several reports suggest that Reg proteins could also be
functional in the nervous system. The Reg-1, a member
of the Reg type I subclass, is expressed in the brain during
development and Alzheimer's disease [13,29]. PAP-I may
contribute to the signaling pathway of ciliary neu-
rotrophic factor and is involved in the regeneration and
survival of motor neurons [30,31]. The expression of
PAP-I has been found to be induced in urinary tract affer-
ent neurons following cyclophosphamide-induced cysti-
tis [32], suggesting its potential role in the abnormal
sensation in cystitis. Moreover, the PAP-I expression in
isolectin B4 (IB4)-positive small DRG neurons is up-reg-
ulated and followed by a dynamic shift from small to large
DRG neurons after peripheral nerve injury [33].
Increased expression of PAP-I also occurs in neurons fol-
lowing traumatic brain injury [34]. These data indicate
that PAP-I expression in response to injury and inflam-
mation could be a general response in the pancreas, intes-
tine, and both peripheral and central nervous systems.
However, it remains unclear whether PAP-II is involved
in the response of primary sensory neurons to the stimu-
lations of peripheral inflammation and nerve injury. The
present study shows that the expression of PAP-II is
strongly induced in DRG neurons following peripheral
tissue inflammation and nerve injury, suggesting an
involvement of PAP-II in the signal processing of the spi-
nal sensory pathways in chronic pain states.
Results
Peripheral inflammation-triggered expression of PAPs in 
small DRG neurons
Increase in expression of PAP-I and -II in the rat DRG
after peripheral tissue inflammation was suggested by our
gene microarray analysis. We found that their expression
was markedly increased in lumbar (L) 4 and L5 DRGs
when peripheral tissue inflammation was induced by
intraplantar CFA injection into the hindpaw of rats. The
microarray signal for PAP-I mRNA was increased by
2394%, 1660% and 1128% at day 2, 4 and 7 after CFA
injection, respectively, while the signal for PAP-II mRNA
was increased by 87% at day 2, 134% at day 4 and 94% at
day 7. These results suggest an inflammation-induced
expression of PAP-I and -II in the DRG.
We then used RT-PCR to confirm the expression of
PAP-I and -II in the rat DRG following peripheral inflam-
mation. The level of PAP-I mRNA was markedly elevated
in the DRG one day after inflammation (Fig. 1A). Such an
increased expression reached the peak level at day 2 and
remained at a reduced level, which was still higher than
control, during 4-7 days after inflammation (Fig. 1A). In
situ hybridization experiments showed that only ~2% of
total neurons in control L4 and L5 DRGs contained PAP-
I mRNA (Fig. 1B and 1C). The number of PAP-I mRNA-
containing neurons was markedly increased to ~28% of
total neurons at inflammation day 2 (Fig. 1B and 1C).
Analysis of cell-size distribution showed that most of
these neurons were small DRG neurons (Fig. 1B). Quanti-
tative analysis showed that the PAP-I mRNA-containing
neuron profiles had a cross-section area ranging from 100
to 1400 μm2 with a peak area between 400 to 700 μm2
(Fig. 1D). There were still ~6% of DRG neurons contain-
ing PAP-I mRNA at day 7 (Fig. 1C). These results indicate
that the expression of PAP-I mRNA is induced in small
DRG neurons after peripheral inflammation.
Similar to PAP-I, only a low level of PAP-II mRNA was
found in L4 and L5 DRGs of normal rats. However, the
expression level of PAP-II was markedly increased in the
DRGs one day after intraplantar CFA injection (Fig. 2A).
Such an elevated expression reached the peak level at day
2, and lasted at least for 7 days (Fig. 2A). In situ hybridiza-
tion histochemistry was then employed to illustrate the
cellular distribution of PAP-II mRNA. We found that less
than ~3% of total neurons contained PAP-II mRNA in the
DRG of control group (Fig. 2B and 2C). However, the per-
centage of PAP-II mRNA-containing DRG neurons was
markedly increased, reaching ~23% of total neurons 2
days after inflammation (Fig. 2B and 2C). Most of these
neurons are small DRG neurons (Fig. 2B and 2D). Seven
days after peripheral inflammation, there were still ~10%
of DRG neurons containing PAP-II mRNA (Fig. 2C).
These results indicate that peripheral tissue inflamma-
tion triggers the expression of PAP-II mRNA in nocicep-
tive small DRG neurons.
Presence of PAP-II in IB4-positive subset of small DRG 
neurons after inflammation
We next asked whether the increase in PAP-II mRNA
resulted in an elevated protein level in small DRG neu-
rons. Immunostaining showed that only ~3% of DRG
neurons of normal rats contained PAP-II (Fig. 3A and
3B), consistent with the result of in situ hybridization.
However, the number of PAP-II-immunoreactive neu-
rons was markedly increased in L4 and L5 DRGs after
peripheral inflammation induced by intraplantar CFA
injection (Fig. 3A and 3B). Quantitative analysis showedHe et al. Molecular Pain 2010, 6:23
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Figure 1 Up-regulation of PAP-I in rat DRGs after peripheral inflammation. (A) RT-PCR shows the increases in PAP-I mRNA levels in L4 and L5 
DRGs after intraplantar CFA injection. (B) In situ hybridization shows that a few small neurons contain PAP-I mRNA in the DRG of normal rats. Two days 
after intraplantar CFA injection, the number of PAP-I mRNA-containing DRG neurons is markedly increased. Scale bar = 200 μm. (C) Time course of the 
up-regulated expression of PAP-I following CFA-induced inflammation shows that the increase in the number of PAP-I mRNA-containing DRG neu-
rons reaches the peak level 2 days after inflammation and, then, is gradually reduced. Quantification was performed on 2~3 sections for each DRG 
from at least three animals at each time point. * P < 0.05, ** P < 0.01 versus control. (D) The PAP-I mRNA-containing neurons are mostly small DRG 
neurons (neuronal cross-section area < 900 μm2, n = 446).He et al. Molecular Pain 2010, 6:23
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Figure 2 Expression of PAP-II in small DRG neurons after peripheral inflammation. (A) RT-PCR shows the increased level of PAP-II mRNA in L4 
and L5 DRGs after intraplantar CFA injection. (B) In situ hybridization shows that PAP-II mRNA is not found in DRG neurons of the normal rat. Two days 
after CFA-induced inflammation, PAP-II mRNA is present in many DRG neurons. Scale bar = 200 μm. (C) The increase in number of PAP-II mRNA-con-
taining DRG neurons reaches the peak level 2 days after CFA injection, and remains at a lower level 7 days after inflammation. Quantification is per-
formed on 2~3 sections for each DRG from at least three animals at each time point. * P < 0.05, ** P < 0.01 versus control. (D) These PAP-II mRNA-
containing neurons are mostly small DRG neurons (neuronal cross-section area < 900 μm2, n = 450).He et al. Molecular Pain 2010, 6:23
http://www.molecularpain.com/content/6/1/23
Page 5 of 12
that ~28% of total DRG neurons in the DRG at inflamma-
tion day 2 contained PAP-II (Fig. 3B). Most of PAP-II-
immunoreactive neuron profiles (n = 220) were small
DRG neurons which had a cross-section area less than
900 μm2, and covered 45% of all small neurons. Although
the number of PAP-II-positive neurons was decreased to
~15% of total neurons at day 4, PAP-II was still present in
many DRG neurons (~16%) at day 7, suggesting a long-
lasting up-regulation of this protein. Thus, peripheral
inflammation induces the expression of PAP-II in small
DRG neurons.
We further identified the subset of small DRG neurons
that expressed PAP-II following peripheral inflammation.
Small DRG neurons can be divided roughly into two sub-
sets, namely the peptidergic subset containing neuropep-
tide substance P and calcitonin gene-related peptide
(CGRP) and non-peptidergic subset positive for IB4,
although there is considerable overlap between these two
subsets of small neurons. Double-immunofluorescence
staining showed that two days after peripheral tissue
inflammation, most of PAP-II-immunoreactive small
DRG neurons (76.7 ± 1.4%) were also IB4-positive, while
26.3 ± 3.0% of PAP-II-positive neurons contained CGRP
(Fig. 4A and 4B). About 89% of PAP-II-positive DRG neu-
rons were also immunostained for peripherin (Fig. 4A
and 4B), a marker for small DRG neuron [35-37]. In con-
trast, PAP-II was absent in Trk-B-immunoreactive DRG
neurons (Fig. 4A), suggesting that inflammation-induced
expression of PAP-II mainly occurs in small DRG neu-
rons. Thus, the expression of PAP-II is induced mainly in
IB4-positive subset of small DRG neurons.
Peripheral nerve injury-induced expression of PAP-II in DRG 
neurons
It has been reported that the P AP-I expression in IB4-
positive small DRG neurons is up-regulated and followed
by a shift from small to large DRG neurons after periph-
eral nerve injury [33]. Therefore, we are interested to
know whether peripheral nerve injury could induce the
expression of PAP-II in DRG neurons. We found that the
expression of PAP-II was also induced in DRG neurons
after peripheral nerve injury. Immunostaining showed
that only ~2% of DRG neurons were positive for PAP-II in
L4 and L5 DRGs on the contralateral side after unilateral
axotomy of the sciatic nerve (Fig. 5A and 5B), similar to
t h a t  f o u n d  i n  t h e  D R G s  o f  n o r m a l  r a t s .  H o w e v e r ,  t h e
number of PAP-II-immunoreactive neurons was mark-
edly increased in the ipsilateral L4 and L5 DRGs (Fig. 5A
and 5B). Quantitative analysis showed that ~13% of total
DRG neurons contained PAP-II in the ipsilateral DRGs 2
days after unilateral axotomy (Fig. 5B). Most of PAP-II-
immunoreactive DRG neurons were small ones at this
time interval (Fig. 5A and 5C).
Fourteen days after unilateral axotomy of the sciatic
nerve, PAP-II was still present in many DRG neurons
(~7% of total neurons), indicating a long-lasting up-regu-
lation of this protein (Fig. 5A and 5B). However, there was
a dynamic shift from small DRG neurons to large ones
(Fig. 5A). In contrast to the presence of PAP-II-immuno-
reactivity in small DRG neurons 2 days after axotomy, the
majority of PAP-II-positive DRG neurons was large ones
(> 900 μm2) 14 days after axotomy (Fig. 5C). Therefore,
the expression of PAP-II is rapidly up-regulated in many
small DRG neurons 2 days after peripheral axotomy, fol-
Figure 3 Increase in PAP-II immunostaining in rat DRGs after peripheral inflammation. (A) Immunohistochemistry shows that the number of 
small DRG neurons immunostained for PAP-II is apparently increased 2 days after CFA injection. (B) The percentage of PAP-II-immunostained small 
DRG neurons is significantly increased from 3.3 ± 1.2% in the control DRGs to 27.6 ± 1.5% in the DRGs 2 days after peripheral inflammation. Such an 
increase of PAP-II-positive DRG neurons is reduced 4 days after inflammation, but remains at the low level 7 days after inflammation. Scale bar = 50 
μm. ** P < 0.01 versus control (n = 7 rats).He et al. Molecular Pain 2010, 6:23
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lowed by reduction in small DRG neurons but further up-
regulation in large neurons.
Distribution of PAP-II in neuropeptide Y-containing large 
DRG neurons after peripheral nerve injury
Double-immunofluorescence staining showed that 2 days
after peripheral nerve injury, most of PAP-II-immunore-
active small DRG neurons were also IB4 or CGRP-nega-
tive (Fig. 6A and 6B), while ~60% of PAP-II-positive DRG
neurons were immunostained for peripherin (Fig. 6A and
6B). It is known that neuropeptide Y (NPY) is expressed
at very low levels in DRG neurons of normal rats, but its
expression is markedly up-regulated in large DRG neu-
rons after peripheral nerve injury [38,39]. Although the
expression of NPY in DRG neurons remained at low lev-
els 2 days after sciatic nerve axotomy, the expression of
PAP-II had already been up-regulated in DRG neurons
including some large neurons (Fig. 6A). Therefore, less
than 10% of PAP-II-positive neurons contained NPY (Fig.
6A), suggesting that nerve injury-induced expression of
PAP-II may represent an early response of DRG neurons
to injury.
The down-regulated expression of CGRP and IB4 in
small DRG neurons, and the up-regulated expression of
NPY in large DRG neurons became predominant 14 days
after sciatic nerve axotomy (Fig. 7A), consistent with pre-
vious studies [38,39]. We found that only a few PAP-II-
containing DRG neurons were immunostained for CGRP
but none for IB4 (Fig. 7A and 7B). Although the percent-
age of PAP-II-positive neurons expressing peripherin was
slightly decreased (from 54.6 ± 10.3% to 48.7 ± 8.7%), co-
expression of PAP-II and peripherin was still present in
small DRG neurons (Fig. 7A and 7B). The number of
large DRG neurons that co-expressed PAP-II and NPY
was markedly increased, contributing to 61.1 ± 2.8% of
total PAP-II-containing DRG neurons (Fig. 7A and 7B).
Thus, the expression of PAP-II can be induced in large
DRG neurons that express NPY 14 days after peripheral
nerve injury.
Anterograde transport of PAP-II in sensory afferent fibers
Although PAP-II-immunoreactivity was found in the cell
bodies of small DRG neurons, we failed to detect its pres-
ence in sensory afferent fibers in lamina I-II of the rat spi-
nal cord. This might be due to either a lack of PAP-II
transport in axons or a rapid release of PAP-II at afferent
terminals. To test these possibilities, we examined
whether PAP-II protein could be transported to nerve
terminals. The sciatic nerve and dorsal root of rats were
ligated for 1 day to attenuate the axonal transport of pro-
teins, resulting in an accumulation of transported protein
near the ligation site. Using immunostaining, we found
that PAP-II was accumulated in the nerve fibers in the
portion of the ligated sciatic nerve and dorsal root that
was proximal to L4 and L5 DRGs but not in the distal
portion (Fig. 8A and 8B), suggesting that PAP-II can be
anterogradely transported to the afferent terminals. After
peripheral tissue inflammation, the accumulation of PAP-
II in the proximal side of the dorsal root and the sciatic
nerve was significantly increased (Fig. 8B and 8C). As a
control, an accumulation of CGRP was also found in the
proximal portion of the ligated sciatic nerve and dorsal
root (data not shown). These results suggest that newly
synthesized PAP-II can be transported to sensory afferent
terminals in the spinal cord and peripheral tissues.
Discussion
The present study shows that expression of PAP-II in
small DRG neurons can be induced by peripheral tissue
Figure 4 Distribution of PAP-II in subsets of small DRG neurons 2 
days after inflammation. (A) Double-immunofluorescence staining 
shows that in the rat DRG the majority of PAP-II-positive small DRG 
neurons do not contain CGRP, but are positive for IB4 2 days after CFA 
injection. Most PAP-II-containing DRG neurons are immunostained for 
peripherin. There is no co-localization of PAP-II and Trk-B in DRG neu-
rons. PAP-II-positive neurons co-expressing other molecules, PAP-II-
negative neurons but containing other molecules and PAP-II-positive 
neurons negative for other molecules are indicated by double arrow-
heads, single arrowhead and arrow, respectively. Scale bar = 50 μm. (B) 
Quantitative analysis shows that 26.3 ± 3% of PAP-II-positive DRG neu-
rons (n = 352) co-express CGRP 2 days after peripheral inflammation, 
and 76.7 ± 1.4% (n = 399) stained for IB4. Most PAP-II-containing DRG 
neurons (89.8 ± 3.3%; n = 293) are immunostained for peripherin.He et al. Molecular Pain 2010, 6:23
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inflammation and nerve injury. Peripheral tissue inflam-
mation causes up-regulated expression of several neuro-
peptides which are normally expressed in DRG neurons,
such as substance P and CGRP [40,41], consistent with
their functional roles in the inflammatory responses
[42,43]. However, PAP-II represents the secretory protein
that is largely absent in DRG neurons under normal cir-
cumstance, but is expressed in these sensory neurons in
response to the inflammatory stimulation and peripheral
nerve injury. These results suggest a potential role of
PAP-II in the modulation of the activity of spinal sensory
circuits in pathological conditions.
In response to peripheral inflammatory stimuli, sub-
stance P and CGRP can be released from peptidergic
afferent terminals to facilitate both peripheral inflamma-
tory responses and nociceptive afferent synaptic trans-
mission in the dorsal spinal cord [40,42,43], indicating a
key role of peptidergic small DRG neurons in inflamma-
tory pain. In the present study, we reveal that the inflam-
mation-induced expression of PAP-II mainly occurs in
IB4-positive subset of small DRG neurons but only in
some peptidergic small DRG neurons, suggesting that
PAP-II may be specifically involved in the inflammatory
response of IB4-positve small DRG neurons. Moreover,
Takahara et al. [32] reported that the expression of PAP-I
was up-regulated in both IB4-positive and TrkA-positive
(peptidergic) small DRG neurons following cyclophosph-
amide-induced cystitis. Therefore, both PAP-I and -II
may contribute to the processing of inflammatory signals
in nociceptive afferent neurons. Interestingly, the inflam-
mation-induced PAP-II expression in IB4-positive subset
of small DRG neurons suggests that this subset of sensory
Figure 5 Increase in PAP-II-immunostained DRG neurons after peripheral nerve injury. (A) Immunohistochemistry shows that the number of 
PAP-II-containing DRG neurons is markedly increased in the rat DRG after sciatic nerve axotomy. Single arrowhead and arrow indicate PAP-II-positive 
small or large DRG neurons, respectively. Scale bar = 50 μm. (B) The percentage of PAP-II-immunostained DRG neurons is significantly increased from 
2.1 ± 0.7% in the DRGs of normal rats to 12.7 ± 0.4% and 6.9 ± 0.6% in the DRGs 2 and 14 days after peripheral axotomy, respectively. * P < 0.05, ** P < 
0.01 versus control (n = 3 rats). (C) Two days after sciatic nerve transection, PAP-II-immunoreactivity is mainly present in small neurons (neuronal cross-
section area < 900 μm2) and a few large neurons (> 900 μm2) (n = 332). Fourteen days after axotomy, the number of PAP-II-positive large DRG neurons 
(n = 514) is markedly increased, whereas the number of PAP-II-containing small neurons is decreased.He et al. Molecular Pain 2010, 6:23
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neurons may play an active role in the inflammatory
response through a relatively selective mechanism, which
might be different from that in peptidergic small DRG
neurons.
In the present study, we failed to show PAP-II-immuno-
reactivity in afferent C- and Aδ-fibers in the superficial
dorsal horn of the spinal cord. However, accumulated
PAP-II was found in the proximal portion of ligated sci-
atic nerve and dorsal root, suggesting an existence of
anterograde transport of this protein to nerve terminals.
Therefore, the absence of PAP-II in afferent fibers might
be due to the constitutive release of the protein. The PAP-
II inhibits the TNF-α-induced inflammatory response in
macrophages [25] and in epithelial and endothelial cells
[26]. Interestingly, TNF-α is one of pro-inflammatory
mediators involved in the sensitization of nociceptors
[44-47]. TNF-α can be anterogradely transported from
the DRG to the sciatic nerve [48] and the spinal cord [49].
This inflammatory mediator acts directly on nociceptive
terminals that express TNF-α receptors [50,51]. Our
present results show the up-regulated expression of PAP-
II in nociceptive DRG neurons and the anterograde trans-
port of PAP-II in sensory afferent fibers, suggesting that
Figure 6 Distribution of PAP-II in DRG neurons 2 days after nerve 
injury. (A) Double-immunofluorescence staining shows that the ma-
jority of PAP-II-positive small DRG neurons are IB4-, CGRP- and NPY-
negative 2 days after sciatic nerve axotomy. However, ~60% of the 
PAP-II-containing DRG neurons are peripherin-immunoreactive. Dou-
ble arrowheads, single arrowhead and arrow indicate PAP-II-positive 
neurons co-expressing other molecules, PAP-II-negative neurons but 
containing other molecules, and PAP-II-positive neurons absent for 
other molecules, respectively. Scale bar = 50 μm. (B) Quantitative anal-
ysis shows that 10.9 ± 1.6% PAP-II-immunoreactive DRG neurons (n = 
271) also express CGRP 2 days after nerve axotomy, while 12.6 ± 2.0% 
(n = 217) and 8.9% ± 1.7% (n = 379) PAP-II-positive DRG neurons are 
stained for IB4 or NPY respectively. More than half of the PAP-II-con-
taining DRG neurons (54.6 ± 10.3%, n = 254) are peripherin-immuno-
reactive neurons.
Figure 7 Distribution of PAP-II in DRG neurons 14 days after 
nerve injury. (A) Double-immunofluorescence staining shows that 
most of PAP-II-positive small DRG neurons do not contain CGRP and 
are also negative for IB4 14 days after sciatic nerve axotomy. However, 
~50% of the PAP-II-positive DRG neurons contain peripherin. More 
than half of PAP-II-positive neurons contain NPY, and most of these 
neurons are large DRG neurons. Double arrowheads, single arrowhead 
and arrow indicate PAP-II-positive neurons co-expressing other mole-
cules, PAP-II-negative neurons but containing other molecules, and 
PAP-II-positive neurons without other molecules, respectively. Scale 
bar = 50 μm. (B) Quantitative analysis shows that 6.3 ± 3.2% (n = 97) 
PAP-II-positive DRG neurons are stained for CGRP 14 days after axoto-
my, but none of PAP-II-positive DRG neurons (n = 120) are positive for 
IB4. About half of the PAP-II-immunoreactive DRG neurons (48.7 ± 
8.7%, n = 136) are peripherin-positive, while 61.1 ± 2.8% (n = 177) of 
PAP-II-positive DRG neurons contain NPY.He et al. Molecular Pain 2010, 6:23
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the PAP-II secreted from sensory afferents might regulate
the pro-inflammatory response of TNF-α in both periph-
eral tissues and the dorsal spinal cord. This may represent
a mechanism for the homeostatic regulation in the
inflammation.
W e  f i n d  h e r e  t h a t  p e r i p h e r a l  i n f l a m m a t i o n  i n d u c e s
expression of both PAP-I and -II in small DRG neurons.
Moreover, these proteins are known to exert the anti-
inflammatory effects in pancreatic-injury [25] and inhibi-
tory effects in TNF-α-induced inflammatory response
[25,26]. Therefore, PAP-I and -II may be involved in both
the inflammatory reaction and the regeneration process
of damaged cells and tissues. Peripheral nerve injury
leads to an up-regulated expression of PAP-I in IB4-posi-
tive small DRG neurons followed by a dynamic shift from
small to large DRG neurons [33]. The present study
shows that peripheral nerve injury induces PAP-II
expression in peripherin-containing small DRG neurons
which mostly expressed neither CGRP nor IB4, followed
by a shift to NPY-containing large DRG neurons 14 days
after peripheral axotomy. This nerve injury-induced dis-
tribution pattern of PAP-II in DRGs is distinct from that
induced by peripheral inflammation, suggesting that the
expression of PAP-II could be regulated through different
mechanisms in pathological conditions.
Interestingly, up-regulation of PAP-II occurs in primary
sensory neurons following both peripheral tissue inflam-
mation and nerve injury that often cause chronic pain. In
addition to the potential roles of PAPs in pain modula-
tion, these proteins may play a role in nerve regeneration
because their expression is markedly up-regulated after
peripheral axotomy, which also initiates the process for
nerve repair. Moreover, the findings of the PAP expres-
sion in IB4-positive neurons following peripheral inflam-
mation and the shift of PAP expression between different
subpopulations of DRG neurons after nerve injury sug-
gest that different populations of DRG neurons may
response to the inflammation and the nerve/tissue dam-
age through relatively selective mechanisms. Therefore, it
would be interesting to further investigate the functional
roles of PAP-II in pathological pain and the related mech-
anisms. Since the patterns of up-regulated expression and
cell distribution of PAP-I and PAP-II in the DRGs appear
to be very similar, it would be necessary to know whether
there is any functional difference between these proteins.
We conclude that both peripheral inflammation and
nerve injury can trigger PAP-II expression in DRG neu-
rons. However, the expression pattern of PAP-II induced
by inflammation is distinct from that induced by nerve
injury. Peripheral inflammation causes PAP-II expression
in IB4-positive small DRG neurons, while PAP-II expres-
sion can be activated in small DRG neurons shortly after
peripheral nerve injury, followed by a shift from small
neurons to large neurons during the later post-injury
days. These results suggest that PAP-II may play potential
roles in the modulation of spinal sensory circuits in path-
ological pain states.
Methods
Animal model and tissue preparation
All interventions and animal care were performed in
accordance with the policy of the Society for Neurosci-
ence (USA) on the use of animals in neuroscience
research and the guidelines of the Committee for
Research and Ethic Issues of International Association for
the Study of Pain. The experiments were approved by the
Committee of Use of Laboratory Animals and Common
facility, Institute of Neuroscience, CAS. All efforts have
been made to minimize the number of animals used and
their discomfort after peripheral inflammation. Sprague-
Dawley male rats (200~250 g, Shanghai Center of Experi-
mental Animals, CAS, Shanghai, China) were anesthe-
tized with sodium pentobarbital (60 mg/kg). Paw
Figure 8 Anterograde transport of PAP-II in afferent fibers. (A, B) 
Immunostaining shows the presence of PAP-II in nerve fibers in the rat 
sciatic nerve and dorsal root that are proximal (PROX, arrowheads) to 
the DRG 24 h after nerve ligation, but absence in the distal (DIST) por-
tion. The number of PAP-II-immunoreactive afferent fibers is increased 
in the proximal portion of ligated sciatic nerve and dorsal root from the 
rat that had undergone inflammation, whereas there is no obvious ac-
cumulation of the protein in the distal side. Scale bar = 50 μm. (C) Sta-
tistical analysis shows that the accumulation of the PAP-II in the 
proximal side of dorsal root is increased by ~200%, and that in the sci-
atic nerve is increased by ~100% (the immunofluorescence intensity 
are measured in the dorsal root and sciatic nerve 500 μm from ligation 
site). * P < 0.05 versus contralateral side (n = 5 rats).He et al. Molecular Pain 2010, 6:23
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inflammation was induced by injection of complete Fre-
und's adjuvant (CFA, Sigma) into the rat plantar subcuta-
neous space of a hindpaw (200 μl/paw). For peripheral
nerve injury model, 5 mm portion of the left sciatic nerve
of rats was transected at mid-thigh level. The rats were
allowed to survive for 1, 2, 4 and 7 days for inflammation
model and 2, 7, 14 and 28 days for nerve injury model (15
rats for each time point for RT-PCR). Axonal transport
was studied by ligating the L4 and L5 dorsal roots and
proximal portion of sciatic nerve (5 rats) at mid-thigh
level 1 day before perfusion fixation. L4 and L5 DRGs of
these rats and of normal rats were then dissected and fro-
zen on dry ice. For in situ hybridization or immunohis-
tochemistry, the same time course was chosen (6 rats for
each time point; 3 rats for in situ hybridization and
immunohistochemistry respectively), and three normal
rats were used as control. The rats were anesthetized and
perfused via the ascending aorta with warm (37°C) saline
followed by warm solution composed of 4% paraformal-
dehyde and 0.2% picric acid in 0.1 M phosphate buffer at
pH 6.9. The perfusion was then followed by 200 ml of the
same fixative (4°C) for another 5 min. L4 and L5 DRGs
and the lumbar spinal cord were then dissected out. The
tissues were post-fixed in the same fixative for 90 min at
4°C, and were then immersed in 10% sucrose in 0.1 M
phosphate buffer for at least 2 days.
Semi-quantitative RT-PCR
Total RNA of normal rat DRGs and that of inflamed or
axotomized rats at different time points were extracted
with TRIzol reagent (Life Technologies). The mRNA was
purified with an Oligotex mRNA kit (Qiagen). The
mRNA (200 ng) of DRGs from normal and inflammatory
or axotomized rats was reverse transcribed to cDNA. The
PCR products were analyzed on 1.5% agarose gel. Glycer-
aldehyde-3-phosphate dehydrogenase (GAPDH) was
used as control. The primers for detection of mRNA
expression were as following: for PAP-I, 5'-TCCTGCCT-
GATGCTCTTA-3' and 5'-TCATTGTTACTCCACTCC
C-3'; for PAP-II, 5'-TGCCCTCTACACGAACCA-3' and
5'-ACTCCACTCCCATCCACC-3'; for GAPDH, 5'-ATC
TCCGCCCCTTCCGCT-3' and 5'-TTGAAGTCACAGG
AGACAACCT-3'.
In situ hybridization
A 600 bp digoxigenin-labeled antisense cRNA riboprobe
spanning the entire PAP-II or PAP-I coding sequence and
3' UTR was generated from PAP-II cDNA as described
previously [52]. DRG sections were fixed in 4% paraform-
aldehyde for 20 min, treated with proteinase K (10 μg/ml
in DEPC water containing 50 mM Tris-HCl, pH 7.5 and 5
mM EDTA) for 20 min, acetylated in 0.25% acetic anhy-
dride/0.1 M triethanolamine (pH 8.0) and prehybridized
in hybridization buffer (50% formamide, 5 × SSC, 0.3 mg/
ml yeast tRNA, 0.1 mg/ml heparin, 1 × Denhardt's solu-
tion, 0.1% Tween-20, 5 mM EDTA in DEPC water) for 4 h
at 65°C. The prehybridization buffer was substituted by
hybridization buffer with 1 μg/ml of the antisense probe
in which the sections were incubated for 14 h at 65°C.
After hybridization, excess probe was removed by wash-
ing three times with 2 × SSC at 67°C and once with RNase
A (1 μg/ml) for 10 min. Sections were then incubated in
alkaline phosphatase-conjugated sheep anti-digoxigenin
antibodies (1:5,000; Roche Molecular Biochemicals), and
then in 1 μl/ml NBT and 3.5 μl/ml BCIP substrates in
alkaline phosphatase buffer (100 mM Tris-HCl, pH 9.5,
50 mM MgCl2, 100 mM NaCl, 0.1% Tween-20 in distilled
water). Control experiments were carried out using a
digoxigenin-labelled sense riboprobe for PAP-I or PAP-II.
For quantitative analysis, 2~3 sections (14 μm-thick)
from each DRG were representative for each rat and the
data were collected from at least three animals at each
time point. To determine the percentage of labelled neu-
ron profiles, the number of positive neuron profiles was
divided by the total number of neuron profiles. To deter-
mine the distribution of labelled neuron within a subset
of DRG neurons, the cross-section area from the neuron
profiles with a clear nucleus was examined and indexed
with 100-μm2 interval. Since the quantitative analysis on
the percentage of the labelled neurons was based on pro-
file counts and, therefore, only provides approximate esti-
mates.
Immunohistochemistry
For all groups, 12 μm-thick sections of the fixed L4 and
L5 DRGs, and L4-5 spinal cord segments were cut in
series in a cryostat and mounted on same gelatin-coated
slides. The sections were processed with indirect immun-
ofluorescence histochemistry. The antibodies were
d i l u t e d  i n  p h o s p h a t e - b u f f e r e d  s a l i n e  w i t h  1 %  b o v i n e
serum albumin and 0.3% Triton X-100. Briefly, the sec-
tions were incubated with a mixture of goat anti-PAP-II
antibodies (1:200; Lifespan Biosciences) and goat anti-
CGRP antibodies (1:5,000; DiaSorin), or rabbit anti-Trk B
antibodies (1:5,000; Santa Cruz), or rabbit anti-peripherin
(1:5,000; Chemicon) overnight at 4°C. To label IB4-posi-
tive small DRG neurons, sections were incubated with
fluorescein-labelled IB4 (1:100; Vector Laboratories).
After several rinses in PBS, the sections were incubated
with fluorescence-conjugated donkey anti-rabbit and
rhodamine-conjugated donkey anti-goat IgG (1:100; Jack-
son ImmunoResearch) for 45 min at 37°C. The sections
were rinsed and mounted with a mixture of glycerol/PBS
(3:1) containing 0.1% paraphenylenediamine and exam-
ined under a Leica SP2 confocal microscope.
For quantitative analysis, 2 sections from each DRG
were representative for each rat and the data were col-
lected from at least three animals at each time point. TheHe et al. Molecular Pain 2010, 6:23
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same calculation for the percentage and the distribution
of labelled neuron profiles each DRG was performed as in
situ  hybridization. For axonal transport analysis, the
immunofluorescence intensity is measured in the dorsal
root and sciatic nerve 500 μm from ligation site.
Statistical analysis
The data were evaluated by unpaired Student's t-test. All
data are shown as mean ± S.E.M. P value < 0.05 was con-
sidered to be significant.
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